Table 2: Epidemiological studies comparing glargine and human insulin with respect to the incidence of cancer.

Study [Ref]DesignComparator insulinMain results

Hemkens et al., 2009 [35]CohortAny humanIncreased risk after adjusting for doses
Colhoun, 2009 [40]CohortAny humanNo effect on overall cancer; increased risk of breast cancer
Jonasson et al., 2009 [45]CohortAny humanNo effect on overall cancer; increased risk of breast cancer
Currie et al., 2009 [34]CohortNPHNo effect
Mannucci et al., 2010 [90]Case-controlNPHNo overall effect; increased overall risk for high doses (>0.3 U/kg*day)
Ljung et al., 2011 [91]CohortAny humanNo effect (new short-term cohort)
Chang et al., 2011 [92]CohortNPHNo effect on overall cancer; increased risk of prostate and pancreas cancer, but not of breast cancer
Morden et al., 2011 [93]CohortAny humanNo effect on overall cancer; increased risk of breast (but not prostate) cancer at high doses (upper quartile)
Ruiter et al., 2012 [95]CohortAny humanReduced risk of overall cancer; dose-dependent increase in the risk of breast and prostate cancer
Suissa et al., 2011 [96]CohortAny humanIncreased risk of breast cancer for long-term (>5 years) use
Lind et al., 2012 [97]CohortAny humanIncreased risk of breast cancer, dose-dependent; nonsignificant trend for prostate cancer
Van Staa et al., 2012 [39]CohortNPHNo effect
Blin et al., 2012 [94]CohortHuman insulinNo effect